CoChat

Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: Role of BDNF-TrkB signaling

Open access
Tan, Yunfei, Fujita, Yuko, Qu, Youge, Chang, Lijia, Pu, Yaoyu, Wang, Siming, Wang, Xingming, Hashimoto, Kenji · 2020 · Pharmacology Biochemistry and Behavior
Cited by 45

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

The N-methyl-d-aspartate receptor (NMDAR) antagonists including phencyclidine (PCP) and ketamine produce cognitive deficits in rodents and humans. We previously reported that (R)-ketamine produced the beneficial effects compared to (S)-ketamine in several animal models including depression. Here we compared the effects of two enantiomers of ketamine on cognitive deficits in mice after repeated administration of PCP. PCP (10 mg/kg/day for 10 days)-induced cognitive deficits were ameliorated by subsequent repeated intermittent administration of (R)-ketamine (10 mg/kg/day, twice weekly for 2-weeks), but not (S)-ketamine. Western blot analysis showed decreased levels of brain-derived neurotrophic factor (BDNF) and decreased ratio of phosphorylated-TrkB (p-TrkB) to TrkB in the prefrontal cortex (PFC) and hippocampus of PCP-treated mice. Furthermore, PCP-induced reduction of BDNF and p-TrkB/TrkB ratio in the PFC and hippocampus of PCP-treated mice was ameliorated by subsequent intermittent administration of (R)-ketamine. Interestingly, the beneficial effects of (R)-ketamine were blocked by pretreatment with TrkB inhibitor ANA-12. These findings suggest that (R)-ketamine could ameliorate PCP-induced cognitive deficits via activation of BDNF-TrkB signaling in the brain. Therefore, (R)-ketamine could be a potential therapeutic drug for cognitive impairment in patients with schizophrenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pbb.2019.172839

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 41

  1. Chaki, 2017, Beyond ketamine: new approaches to the development of safer antidepressants, Curr. Neuropharmacol., 15, 963, 10.2174/1570159X15666170221101054 · DOI · Paper page
  2. Coyle, 2017, Schizophrenia: basic and clinical, Adv. Neurobiol., 15, 255, 10.1007/978-3-319-57193-5_9 · DOI
  3. Domino, 2010, Taming the ketamine tiger. 1965, Anesthesiology, 113, 678, 10.1097/ALN.0b013e3181ed09a2 · DOI · Paper page
  4. Domino, 2012, Phencyclidine/schizophrenia: one view toward the past, the other to the future, Schizophr. Bull., 38, 914, 10.1093/schbul/sbs011 · DOI · Paper page
  5. Fujita, 2019, MPTP-induced dopaminergic neurotoxicity in mouse striatum is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling, Psychopharmacology
  6. Goff, 2011, The treatment of cognitive impairment in schizophrenia, Pharmacol. Biochem. Behav., 99, 245, 10.1016/j.pbb.2010.11.009 · DOI · Paper page
  7. Green, 1996, What are the functional consequences of neurocognitive deficits in schizophrenia?, Am. J. Psychiatry, 153, 321, 10.1176/ajp.153.3.321 · DOI · Paper page
  8. Hashimoto, 2014, Targeting of NMDA receptors in new treatments for schizophrenia, Expert Opin. Ther. Targets, 18, 1049, 10.1517/14728222.2014.934225 · DOI · Paper page
  9. Hashimoto, 2016, R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity, Psychol. Med., 46, 2449, 10.1017/S0033291716000969 · DOI · Paper page
  10. Hashimoto, 2016, Ketamine’s antidepressant action: beyond NMDA receptor inhibition, Expert Opin. Ther. Targets, 20, 1389, 10.1080/14728222.2016.1238899 · DOI · Paper page
  11. Hashimoto, 2019, Recent advances in the early intervention in schizophrenia: future direction from preclinical findings, Curr. Psychiatr. Rev., 21, 75
  12. Hashimoto, 2007, Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors, Neuropsychopharmacology, 32, 514, 10.1038/sj.npp.1301047 · DOI
  13. Hashimoto, 2005, Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol, Eur. J. Pharmacol., 519, 114, 10.1016/j.ejphar.2005.07.002 · DOI
  14. Hashimoto, 2008, Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711, Biol. Psychiatry, 63, 92, 10.1016/j.biopsych.2007.04.034 · DOI
  15. Hashimoto, 2013, Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders, Eur. Arch. Psychiatry Clin. Neurosci., 263, 367, 10.1007/s00406-013-0399-y · DOI · Paper page
  16. Hida, 2015, Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC, Neuropsychopharmacology, 40, 601, 10.1038/npp.2014.207 · DOI · Paper page
  17. Javitt, 1991, Recent advances in the phencyclidine model of schizophrenia, Am. J. Psychiatry, 148, 1301, 10.1176/ajp.148.10.1301 · DOI · Paper page
  18. Jentsch, 1999, The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia, Neuropsychopharmacology, 20, 201, 10.1016/S0893-133X(98)00060-8 · DOI · Paper page
  19. Kaur, 2019, Esketamine: a glimmer of hope in treatment-resistant depression, Eur. Arch. Psychiatry Clin. Neurosci.
  20. Krystal, 1994, Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses, Arch. Gen. Psychiatry, 51, 199, 10.1001/archpsyc.1994.03950030035004 · DOI · Paper page
  21. Krystal, 2019, Ketamine: a paradigm shift for depression research and treatment, Neuron, 101, 774, 10.1016/j.neuron.2019.02.005 · DOI · Paper page
  22. Li, 2018, The effects of donepezil on phencyclidine-induced cognitive deficits in a mouse model of schizophrenia, Pharmacol. Biochem. Behav., 175, 69, 10.1016/j.pbb.2018.09.006 · DOI
  23. Lin, 2019, Early identification and intervention of schizophrenia: insight from hypotheses of glutamate dysfunction and oxidative stress, Front. Psych., 10, 93, 10.3389/fpsyt.2019.00093 · DOI
  24. Lin, 2019, Novel treatment for the hardest-to-treat schizophrenia: dual action of NMDA receptor and antioxidant, Curr. Drug Targets
  25. Man, 2018, Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia, Psychiatry Res., 263, 1, 10.1016/j.psychres.2018.02.034 · DOI
  26. Masaki, 2019, (R)- and (S)-ketamine induce differential fMRI responses in conscious rats, Synapse, 73, 10.1002/syn.22126 · DOI · Paper page
  27. McShane, 2019, Esketamine and the need for a new type of registry for drugs with abuse potential, Am. J. Psychiatry, 176, 966, 10.1176/appi.ajp.2019.19060631 · DOI
  28. Morris, 2005, PCP: from pharmacology to modelling schizophrenia, Curr. Opin. Pharmacol., 5, 101, 10.1016/j.coph.2004.08.008 · DOI · Paper page
  29. Nakazawa, 2019, The origin of NMDA receptor hypofunction in schizophrenia, Pharmacol. Ther.
  30. Ren, 2015, BDNF–TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms, Transl. Psychiatry, 5, e666, 10.1038/tp.2015.157 · DOI · Paper page
  31. Shirai, 2015, Dietary intake of sulforaphane-rich broccoli sprout extracts during juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at adulthood, PLoS One, 10, 10.1371/journal.pone.0127244 · DOI · Paper page
  32. Singh, 2017, Ketamine treatment for depression: opportunities for clinical innovation and ethica foresight, Lancet Psychiatry, 4, 419, 10.1016/S2215-0366(17)30102-5 · DOI · Paper page
  33. Snigdha, 2011, Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain, J. Mol. Neurosci., 43, 337, 10.1007/s12031-010-9447-5 · DOI · Paper page
  34. Tian, 2018, Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine, Pharmacol. Biochem. Behav., 172, 17, 10.1016/j.pbb.2018.07.003 · DOI · Paper page
  35. Yang, 2018, Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model, Biol. Psychiatry, 83, 18, 10.1016/j.biopsych.2017.05.016 · DOI · Paper page
  36. Yang, 2019, Brain-derived neurotrophic factor is associated with cognitive impairments in first-episode and chronic schizophrenia, Psychiatry Res., 273, 528, 10.1016/j.psychres.2019.01.051 · DOI · Paper page
  37. Yoshimi, 2014, Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors, Pharmacol. Biochem. Behav., 124, 245, 10.1016/j.pbb.2014.06.008 · DOI
  38. Zhang, 2019, An update on ketamine and its two enantiomers as rapid-acting antidepressants, Expert. Rev. Neurother., 19, 83, 10.1080/14737175.2019.1554434 · DOI · Paper page
  39. Zhang, 2012, Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia, Psychopharmacology, 222, 277, 10.1007/s00213-012-2643-y · DOI
  40. Zhang, 2014, R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine, Pharmacol. Biochem. Behav., 116, 137, 10.1016/j.pbb.2013.11.033 · DOI · Paper page
  41. Zhang, 2018, Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study, Psychopharmacology, 235, 1191, 10.1007/s00213-018-4835-6 · DOI

Cited by

See all 45

Metadata

Authors
Tan, Y., Fujita, Y., Qu, Y., Chang, L., Pu, Y., Wang, S., Wang, X., & Hashimoto, K.
Venue
Pharmacology Biochemistry and Behavior
Publisher
Elsevier BV
Published
2020-01
Volume
188
Pages
172839
ISSN
0091-3057 (ISSN-L)
OpenAlex
W2996581715
Cited by
45
References
17
FWCI
3.39
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
Japan Agency for Medical Research and Development

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: Role of BDNF-TrkB signaling. https://app.cochat.ai/papers/10.1016/j.pbb.2019.172839
The paper
Tan, Y., Fujita, Y., Qu, Y., Chang, L., Pu, Y., Wang, S., Wang, X., & Hashimoto, K. (2020). Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: Role of BDNF-TrkB signaling. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2019.172839

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.